CBD Partially Blocks THC Metabolism in the Liver, With Women Showing Higher THC Blood Levels Than Men | Research

The takeaway

A double-blind study of 24 volunteers found evidence that CBD partially inhibits the liver enzyme that converts THC to its active metabolite 11-OH-THC, though the effect was small compared to natural individual variation, and women had significantly higher THC blood levels than men.

Read this if you use cannabis products containing both THC and CBD and want to understand how CBD might affect how your body processes THC.

Women had significantly higher THC blood levels (Cmax and AUC) and faster absorption than men

What the researchers found

Twenty-four volunteers (12 male, 12 female) received soft-gelatin capsules of either 10 mg THC alone, cannabis extract containing 10 mg THC plus 5.4 mg CBD, or placebo in a crossover design. Blood samples were collected over 24 hours and analyzed for THC, 11-OH-THC, THC-COOH, and CBD.

Despite large individual variation in the data, evidence emerged that CBD partially inhibits the CYP 2C enzyme that hydroxylates THC to 11-OH-THC. This inhibition is likely most relevant for oral intake because THC and CBD reach relatively high liver concentrations and because of THC's substantial first-pass metabolism.

However, the effect of CBD was small compared to variability from other factors. A notable secondary finding was that women had significantly higher peak concentrations (Cmax) and total exposure (AUC) of THC, and reached peak levels faster (shorter tmax) than men.

Why it matters

The finding that CBD partially inhibits THC metabolism has implications for dosing cannabis-based medicines. If CBD reduces THC conversion to its active metabolite, the ratio of THC to CBD in a product could affect the pharmacological profile. The sex difference finding also suggests men and women may need different dosing considerations.

The numbers in context

24 volunteers (12 male, 12 female). Doses: 10 mg THC alone or 10 mg THC + 5.4 mg CBD. Blood sampled at 9 time points over 24 hours. CBD partially inhibits CYP 2C-mediated THC hydroxylation. Women had significantly higher Cmax and AUC for THC than men.

How the study worked

Double-blind, placebo-controlled, crossover study in 24 volunteers (12 male, 12 female, age 18-45). Three conditions at weekly intervals: 10 mg THC capsules, cannabis extract (10 mg THC + 5.4 mg CBD), or placebo. Blood samples at 9 time points over 24 hours. THC and metabolites measured by solid phase extraction, derivatization, and GC-MS. Pharmacokinetic parameters compared statistically.

What this study cannot tell us

Large individual variation in pharmacokinetic data made it difficult to detect definitive effects. The doses used (10 mg THC, 5.4 mg CBD) may not represent all clinical scenarios. The study concluded the pharmacokinetic interaction is unlikely to explain clinical differences between pure THC and cannabis extract at these doses. Only single-dose pharmacokinetics were assessed.

How to read the evidence

Well-designed double-blind, placebo-controlled crossover study with rigorous pharmacokinetic analysis. Adequate sample size for pharmacokinetic work. High individual variability limited definitive conclusions.

When this study was published

Published in 2005. Understanding of CBD-THC pharmacokinetic interactions has advanced since then, with more studies examining different dose ratios and delivery methods.

The bigger picture

Understanding how CBD affects THC metabolism is critical for developing standardized cannabis-based medicines. This study provides pharmacokinetic evidence that the THC-to-CBD ratio matters not just for pharmacodynamic (receptor-level) interactions but also for how the body processes THC. The sex difference finding adds another layer of complexity to cannabis dosing.

Questions still open

At what CBD-to-THC ratios does the metabolic inhibition become clinically significant? Should dosing recommendations for cannabis-based medicines differ between men and women?

Common questions

Does CBD change how the body processes THC?

This study found evidence that CBD partially inhibits the liver enzyme (CYP 2C) responsible for converting THC to its active metabolite 11-OH-THC. This effect is most relevant when both are taken orally, as they pass through the liver. However, the effect was small compared to natural individual variation.

Do men and women process THC differently?

Yes. Women in this study had significantly higher peak THC concentrations and total THC exposure than men given the same dose, and reached peak levels faster. This suggests biological sex affects THC pharmacokinetics and may be relevant for dosing.

Read the original research

Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.

Therapeutic drug monitoring, 27(6), 799-810

View on PubMed ↗

Citation

Nadulski, Thomas; Pragst, Fritz; Weinberg, Gordon; Roser, Patrik; Schnelle, Martin; Fronk, Eva-Maria; Stadelmann, Andreas Michael. (2005). Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.. Therapeutic drug monitoring, 27(6), 799-810.